Potential role of rivaroxaban in patients with acute coronary syndrome

por Fitchett, David H
Publicado 2012

Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease – Implications for Clinical Practice

por Fitchett, David H
Publicado 2018

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial

por Inzucchi, Silvio E, Khunti, Kamlesh, Fitchett, David H, Wanner, Christoph, Mattheus, Michaela, George, Jyothis T, Ofstad, Anne Pernille, Zinman, Bernard
Publicado 2020

Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome

por Fitchett, David H., Leiter, Lawrence A., Lin, Peter, Pickering, Jennifer, Welsh, Robert, Stone, James, Gregoire, Jean, McFarlane, Philip, Langer, Anatoly, Gupta, Anil, Goodman, Shaun G.
Publicado 2020

Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial

por Ferreira, João Pedro, Kraus, Bettina Johanna, Zwiener, Isabella, Lauer, Sabine, Zinman, Bernard, Fitchett, David H., Koitka‐Weber, Audrey, George, Jyothis T., Ofstad, Anne Pernille, Wanner, Christoph, Zannad, Faiez
Publicado 2021

Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial

por Vaduganathan, Muthiah, Inzucchi, Silvio E., Sattar, Naveed, Fitchett, David H., Ofstad, Anne Pernille, Brueckmann, Martina, George, Jyothis T., Verma, Subodh, Mattheus, Michaela, Wanner, Christoph, Zinman, Bernard, Butler, Javed
Publicado 2021